{"id":"hydrocortisone-modified-release-capsules","safety":{"commonSideEffects":[{"rate":"10%","effect":"Hypertension"},{"rate":"8%","effect":"Hyperglycemia"},{"rate":"5%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Hydrocortisone modified release capsules work by activating the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects.","oneSentence":"Glucocorticoid receptor agonist","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:22:58.733Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Eczema"},{"name":"Psoriasis"},{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT05299554","phase":"PHASE3","title":"Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2022-04-01","conditions":"Congenital Adrenal Hyperplasia","enrollment":76},{"nctId":"NCT05063994","phase":"PHASE3","title":"Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2022-05-24","conditions":"Congenital Adrenal Hyperplasia","enrollment":55},{"nctId":"NCT05222152","phase":"PHASE2","title":"Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2021-11-23","conditions":"Primary Adrenal Insufficiency","enrollment":58},{"nctId":"NCT03532022","phase":"PHASE3","title":"Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy","status":"WITHDRAWN","sponsor":"Neurocrine UK Limited","startDate":"2018-10-04","conditions":"Congenital Adrenal Hyperplasia","enrollment":""},{"nctId":"NCT02716818","phase":"PHASE3","title":"Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2016-02-22","conditions":"Congenital Adrenal Hyperplasia","enrollment":122},{"nctId":"NCT01735617","phase":"PHASE2","title":"Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2012-12","conditions":"Endocrine Disease, Adrenal Insufficiency, Congenital Adrenal Hyperplasia","enrollment":16},{"nctId":"NCT03019614","phase":"PHASE1","title":"An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2010-03","conditions":"Congenital Adrenal Hyperplasia, Adrenal Insufficiency","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Chronocort"],"phase":"phase_2","status":"active","brandName":"Hydrocortisone Modified Release Capsules","genericName":"Hydrocortisone Modified Release Capsules","companyName":"Neurocrine UK Limited","companyId":"neurocrine-uk-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glucocorticoid receptor agonist Used for Eczema, Psoriasis, Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}